Liquid chromatographic assay for the cyclic depsipeptide aplidine, a new marine antitumor drug, in whole blood using derivatization with trans-4′-hydrazino-2-stilbazole
✍ Scribed by Rolf W. Sparidans; Jan H. M. Schellens; Luis López-Lázaro; José M. Jimeno; Jos H. Beijnen
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 86 KB
- Volume
- 18
- Category
- Article
- ISSN
- 0269-3879
- DOI
- 10.1002/bmc.286
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
A sensitive bio‐analytical assay for the depsipeptide aplidine in plasma has been modified and tested for human whole blood samples. The adapted method is based on reversed‐phase liquid chromatography and fluorescence detection of the trans‐4′‐hydrazino‐2‐stilbazole derivative of the analyte. Aplidine is isolated from the matrix by solid‐phase extraction on an octadecyl modified silica stationary phase. After evaporation of the acetone eluate, the derivatization with the hydrazino reagent is performed in a water–acetonitrile mixture at pH = 4. The reaction mixture is injected directly into the chromatograph and the analyte is quantified by fluorescence detection at 410 and 560 nm for excitation and emission, respectively. The method has been validated in the 2–100 ng/mL range, with 2 ng/mL being the lower limit of quantification. Precision and accuracy both meet the current requirements for a bioanalytical assay. The stability of aplidine in whole blood at ambient temperature and at 37°C is limited; recoveries in the range 60–85% were observed after 7 h. Further, adequate stability of aplidine in plasma at −80 and −20°C for 35 months could now be demonstrated. Copyright © 2003 John Wiley & Sons, Ltd.